Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2026-01-02 00:00:00 ET · period of report 2026-01-02 · accession 0001864159-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | 2026-01-02 | JANX | Meyer Andrew Hollman | Chief Business Off | S - Sale | $13.73 | -1,879 | 83.1K | -2% | -$25.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | S | D | 1,879 | $13.73 | 83,095 | D | — | — |